Atorvastatin use in specific populations: Difference between revisions

Jump to navigation Jump to search
No edit summary
mNo edit summary
Line 10: Line 10:
==References==
==References==
{{Reflist}}
{{Reflist}}
{{FDA}}
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Revision as of 21:16, 30 January 2014

Atorvastatin
Lipitor® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]


Hepatic impairment: Plasma concentrations markedly increased in patients with chronic alcoholic liver disease.[1]


References

  1. "LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC]".

Adapted from the FDA Package Insert.